Alibaba, Baidu shares soar on reported shift to in-house AI chips
Beta Bionics, Inc. (NASDAQ:BBNX) Chief Product Officer Mike Mensinger sold 1,089 shares of common stock on September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $18.8632, realizing approximately $20,542. Prices for the sale ranged from $18.58 to $19.09. The stock, currently trading at $20.1, has shown strong momentum with a 7.4% gain in the past week. According to InvestingPro analysis, technical indicators suggest the stock is in overbought territory.
Following the transaction, Mensinger directly owns 91,815 shares of Beta Bionics, Inc. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. With a market capitalization of $819 million and analyst price targets ranging from $17 to $30, InvestingPro data indicates the stock is trading above its Fair Value. Subscribers can access 6 additional ProTips and a comprehensive Pro Research Report for deeper insights into BBNX’s financial health and growth prospects.
In other recent news, Beta Bionics Inc . reported its second-quarter earnings for 2025, showcasing significant financial improvements. The company achieved an earnings per share of -$0.39, surpassing the forecast of -$0.42. Additionally, Beta Bionics experienced a 54% year-over-year increase in net sales, reaching $23.2 million. This strong performance was driven by higher-than-expected new patient starts and success in the pharmacy benefit provider channel. Truist Securities responded by raising its price target for Beta Bionics from $18.00 to $21.00, while maintaining a Buy rating. These developments highlight the company’s positive trajectory and the confidence analysts have in its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.